Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration 2-05-2025, 15:59

At CPHI Frankfurt, TekniPlex Healthcare to Present Full Range of Barrier Blister Films, Customized Liquid Drug Delivery Solutions and Live Demonstrations of Latest Filling-Sealing Machine 17-09-2025, 21:00